» Articles » PMID: 16839203

Carrageenan is a Potent Inhibitor of Papillomavirus Infection

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2006 Jul 15
PMID 16839203
Citations 214
Authors
Affiliations
Soon will be listed here.
Abstract

Certain sexually transmitted human papillomavirus (HPV) types are causally associated with the development of cervical cancer. Our recent development of high-titer HPV pseudoviruses has made it possible to perform high-throughput in vitro screens to identify HPV infection inhibitors. Comparison of a variety of compounds revealed that carrageenan, a type of sulfated polysaccharide extracted from red algae, is an extremely potent infection inhibitor for a broad range of sexually transmitted HPVs. Although carrageenan can inhibit herpes simplex viruses and some strains of HIV in vitro, genital HPVs are about a thousand-fold more susceptible, with 50% inhibitory doses in the low ng/ml range. Carrageenan acts primarily by preventing the binding of HPV virions to cells. This finding is consistent with the fact that carrageenan resembles heparan sulfate, an HPV cell-attachment factor. However, carrageenan is three orders of magnitude more potent than heparin, a form of cell-free heparan sulfate that has been regarded as a highly effective model HPV inhibitor. Carrageenan can also block HPV infection through a second, postattachment heparan sulfate-independent effect. Carrageenan is in widespread commercial use as a thickener in a variety of cosmetic and food products, ranging from sexual lubricants to infant feeding formulas. Some of these products block HPV infectivity in vitro, even when diluted a million-fold. Clinical trials are needed to determine whether carrageenan-based products are effective as topical microbicides against genital HPVs.

Citing Articles

Plant Compounds Inhibit the Growth of W12 Cervical Precancer Cells Containing Episomal or Integrant HPV DNA; Tanshinone IIA Synergizes with Curcumin in Cervical Cancer Cells.

Einbond L, Zhou J, Huang K, Castellanos M, Mbazor E, Balick M Viruses. 2025; 17(1).

PMID: 39861845 PMC: 11768664. DOI: 10.3390/v17010055.


Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037).

Ho K, Hoesley C, Anderson P, Fernandez-Romero J, Friedland B, Kelly C J Acquir Immune Defic Syndr. 2025; 97(4):379-386.

PMID: 39808074 PMC: 11733313. DOI: 10.1097/QAI.0000000000003506.


HSPG-binding peptide Pep19-2.5 is a potent inhibitor of HPV16 infection.

Mikulicic S, Massenberg A, Doring T, Brandenburg K, Lang T, Florin L Antimicrob Agents Chemother. 2025; 69(2):e0157524.

PMID: 39807885 PMC: 11823620. DOI: 10.1128/aac.01575-24.


Algae a Potential Source in Cosmetics: Current Status, Challenges, and Economic Implications.

Saini K, Rani A, Gupta S, Sharma P Indian J Microbiol. 2024; 64(4):1445-1460.

PMID: 39678953 PMC: 11645359. DOI: 10.1007/s12088-024-01263-0.


A Comprehensive Evaluation of the HPV Neutralizing Antibodies in Guangzhou, China: A Comparative Study on Various HPV Vaccines.

Zha R, Liao C, Lin D, Zhao L, Chen Y, Yao L Vaccines (Basel). 2024; 12(11).

PMID: 39591188 PMC: 11599073. DOI: 10.3390/vaccines12111286.


References
1.
Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J . Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol. 2000; 74(4):1948-60. PMC: 111673. DOI: 10.1128/jvi.74.4.1948-1960.2000. View

2.
Magnuson B, Rainey E, Benjamin T, Baryshev M, Mkrtchian S, Tsai B . ERp29 triggers a conformational change in polyomavirus to stimulate membrane binding. Mol Cell. 2005; 20(2):289-300. DOI: 10.1016/j.molcel.2005.08.034. View

3.
Pastrana D, Vass W, Lowy D, Schiller J . NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology. 2001; 279(1):361-9. DOI: 10.1006/viro.2000.0702. View

4.
Coggins C, Blanchard K, Alvarez F, Brache V, Weisberg E, Kilmarx P . Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm Infect. 2001; 76(6):480-3. PMC: 1744249. DOI: 10.1136/sti.76.6.480. View

5.
Tobacman J . Review of harmful gastrointestinal effects of carrageenan in animal experiments. Environ Health Perspect. 2001; 109(10):983-94. PMC: 1242073. DOI: 10.1289/ehp.01109983. View